- Home
- PSF vs AMRN Comparison
PSF vs AMRN Comparison
Compare PSF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- AMRN
- Stock Information
- Founded
- PSF 2010
- AMRN 1989
- Country
- PSF United States
- AMRN Ireland
- Employees
- PSF N/A
- AMRN N/A
- Industry
- PSF Investment Managers
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- AMRN Health Care
- Exchange
- PSF Nasdaq
- AMRN Nasdaq
- Market Cap
- PSF 256.1M
- AMRN 234.4M
- IPO Year
- PSF N/A
- AMRN 1993
- Fundamental
- Price
- PSF $21.00
- AMRN $0.58
- Analyst Decision
- PSF
- AMRN Hold
- Analyst Count
- PSF 0
- AMRN 3
- Target Price
- PSF N/A
- AMRN $1.00
- AVG Volume (30 Days)
- PSF 25.0K
- AMRN 717.1K
- Earning Date
- PSF 01-01-0001
- AMRN 10-30-2024
- Dividend Yield
- PSF 7.69%
- AMRN N/A
- EPS Growth
- PSF N/A
- AMRN N/A
- EPS
- PSF N/A
- AMRN N/A
- Revenue
- PSF N/A
- AMRN $264,779,000.00
- Revenue This Year
- PSF N/A
- AMRN N/A
- Revenue Next Year
- PSF N/A
- AMRN N/A
- P/E Ratio
- PSF N/A
- AMRN N/A
- Revenue Growth
- PSF N/A
- AMRN N/A
- 52 Week Low
- PSF $16.00
- AMRN $0.56
- 52 Week High
- PSF $20.19
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- PSF 48.71
- AMRN 44.88
- Support Level
- PSF $21.11
- AMRN $0.56
- Resistance Level
- PSF $21.39
- AMRN $0.61
- Average True Range (ATR)
- PSF 0.17
- AMRN 0.03
- MACD
- PSF -0.06
- AMRN 0.00
- Stochastic Oscillator
- PSF 2.42
- AMRN 15.00
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.